Discover
ELVN
Enliven Therapeutics, Inc.
44.25
2 x 32.21
2 x 56.83
bid
ask
-
0.83
1.84%
2 @ 04:00 PM
44.25 +0.00 (0.00%)
| Ytd | 187.34% | |
| 1y | 84.61% |
44.09
day range
45.87
14.79
52 week range
62.32
| Open | 44.92 | Prev Close | 45.08 | Low | 44.09 | High | 45.87 | Mkt Cap | 3.24B |
| Vol | 1.24M | Avg Vol | 1.35M | EPS | -1.67 | P/E | N/A | Forward P/E | -19.10 |
| Beta | 0.34 | Short Ratio | 5.98 | Inst. Own | 115.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 49.00 | 200-d Avg | 42.64 | 1yr Est | 74.42 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | -0.45 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | -0.39 | -0.49 | -0.1 | -26.56% |
| 2026-05-07 | 2026-03 | -0.44 | -0.38 | 0.06 | 13.64% |
| 2026-03-03 | 2025-12 | -0.42 | -0.48 | -0.06 | -14.29% |
| 2025-11-12 | 2025-09 | -0.43 | -0.32 | 0.11 | 25.58% |
| 2025-08-13 | 2025-06 | -0.53 | -0.49 | 0.04 | 7.55% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-10-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-10-02 | Morgan Stanley | Upgrade | Overweight | |
| 2026-10-01 | JP Morgan | Upgrade | Overweight | |
| 2026-08-18 | William Blair | Upgrade | Outperform | |
| 2026-08-18 | Barclays | Upgrade | Overweight | |
| 2026-08-18 | Mizuho | Upgrade | Outperform | Outperform |
Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-10-18 | COLLINS HELEN LOUISE | Officer | 25.00K | Sale |
| 2026-08-03 | DERYNCK MIKA K | Director | 0.00 | Sale |
| 2026-09-30 | GARLAND J SCOTT | Director | 0.00 | Sale |
| 2026-02-16 | HEYMAN RICHARD A | Director | 0.00 | Sale |
| 2026-10-18 | HOHL BENJAMIN | Chief Financial Officer | 38.00K | Sale |
| 2025-11-16 | KINTZ SAMUEL | Chief Executive Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 10.03M | 443.61M | 13.68% |
| 2026-06-29 | Orbimed Advisors LLC. | 6.78M | 299.87M | 9.25% |
| 2026-06-29 | Polar Capital Holdings PLC | 6.43M | 284.56M | 8.78% |
| 2026-06-29 | Blackrock Inc. | 4.36M | 192.92M | 5.95% |
| 2026-06-29 | Vestal Point Capital, LP | 4.00M | 177.00M | 5.46% |
| 2026-06-29 | Commodore Capital Lp | 3.28M | 144.92M | 4.47% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.88M | 83.34M | 2.57% |
| 2026-09-29 | iShares Trust-iShares Russell 2000 ETF | 1.51M | 66.75M | 2.06% |
| 2026-08-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 1.28M | 56.64M | 1.75% |
| 2026-07-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.25M | 55.35M | 1.71% |
| 2026-06-29 | T. Rowe Price New Horizons Fund, Inc. | 807.33K | 35.72M | 1.10% |
| 2026-08-30 | Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 737.60K | 32.64M | 1.01% |